DOCSLIB.ORG

Medical Students and SARS-Cov-2 Vaccination: Attitude and Behaviors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medical Students and SARS-Cov-2 Vaccination: Attitude and Behaviors Article Medical Students and SARS-CoV-2 Vaccination: Attitude and Behaviors Bartosz Szmyd 1 , Adrian Bartoszek 1,2,*, Filip Franciszek Karuga 1,3 , Katarzyna Staniecka 1, Maciej Błaszczyk 1 and Maciej Radek 1 1 Department of Neurosurgery, Spine and Peripheral Nerves Surgery of Medical University of Lodz, 90-549 Łód´z,Poland; [email protected] (B.S.); fi[email protected] (F.F.K.); [email protected] (K.S.); [email protected] (M.B.); [email protected] (M.R.) 2 Department of Pathophysiology, Medical University of Lublin, 20-090 Lublin, Poland 3 Department of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, 92-215 Łódz, Poland * Correspondence: [email protected] Abstract: Since physicians play a key role in vaccination, the initial training of medical students (MS) should aim to help shape their attitude in this regard. The beginning of vaccination programs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an excellent time to assess the attitudes held by both medical and non-medical students regarding vaccination. A 51- to 53- item questionnaire including the Depression, Anxiety and Stress Scale was administered to 1971 students (49.21% male; 34.86% MS); two career-related questions were also addressed to the MS. The majority of surveyed students indicated a desire to get vaccinated against SARS-CoV-2, with more medical than non-medical students planning to get vaccinated (91.99% vs. 59.42%). The most common concern about SARS-CoV-2 infection was the risk of passing on the disease to elderly relatives. While conspiracy theories regarding the COVID-19 vaccine are less popular among MS, Citation: Szmyd, B.; Bartoszek, A.; both groups indicated concerns that vaccines may cause autism is equally common (~5%). Further Karuga, F.F.; Staniecka, K.; Błaszczyk, studies exploring social attitudes towards the SARS-CoV-2 vaccine are a necessary first step to M.; Radek, M. Medical Students and optimizing vaccination programs and achieving herd immunity. SARS-CoV-2 Vaccination: Attitude and Behaviors. Vaccines 2021, 9, 128. Keywords: COVID-19; SARS-CoV-2; vaccination; healthcare workers; depression; anxiety; stress https://doi.org/10.3390/ vaccines9020128 Academic Editor: 1. Introduction Vasso Apostolopoulos As physicians play a key role in vaccination, the initial training of medical students Received: 5 January 2021 (MS) should not only provide accurate medical knowledge but should also help shape Accepted: 3 February 2021 Published: 5 February 2021 attitudes regarding the topic [1]. Unfortunately, nearly a third of final-year MS feel inade- quately prepared to deal with the clinical aspects of vaccination, especially communication Publisher’s Note: MDPI stays neutral issues with vaccine-hesitant patients [1]. This may well be a product of the excessive with regard to jurisdictional claims in focus on theoretical knowledge typified in educational programs and the resulting lack of published maps and institutional affil- practical skills [2]. This limitation of current medical training is highlighted by the fact that iations. the Internet is considered to be a better source of information about vaccines than medical studies (59% vs. 52% of MS, respectively) [3]. Other significant determinants of vaccine uptake include the clinical years of medical study and any previous history of recommended vaccination (e.g., against influenza) [1,4,5]. The current public debate about vaccination against severe acute respiratory syndrome Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. coronavirus 2 (SARS-CoV-2) is not only a good opportunity to assess student attitudes This article is an open access article and behaviors toward vaccination, but also to examine the psychological environment distributed under the terms and of the students resulting from this situation, such as any depression, anxiety, and stress conditions of the Creative Commons symptoms. Therefore, the present study attempts to identify any relationship between the Attribution (CC BY) license (https:// aforementioned factors, as well as the current state of knowledge regarding vaccination creativecommons.org/licenses/by/ among students, and their readiness to become vaccinated against SARS-CoV-2. We 4.0/). hypothesize that: Vaccines 2021, 9, 128. https://doi.org/10.3390/vaccines9020128 https://www.mdpi.com/journal/vaccines Vaccines 2021, 9, 128 2 of 12 • medical studies form pro-vaccination behaviors; • depression, anxiety, and stress related to the public debate on vaccination increase the willingness to get vaccinated. 2. Materials and Methods 2.1. Study Design and Participants An online survey was performed among Polish medical (MS) and nonmedical students (NMS; control group). NMS comprised all students except those of dentistry, dietetics, emer- gency medical services, laboratory diagnostics, medicine, nursing, obstetrics, pharmacy, and physiotherapy students. The self-administered online questionnaire was available on Google Forms between 22 and 25 December 2020, during the public debate on SARC-CoV-2 vaccination, before the first vaccination rollout in Poland on 27 December 2020 (including healthcare workers and students of medical faculties). All MS were invited to take the survey through institutional emails, university-affiliated websites, and social media profiles (Facebook). However, as the authors only had access to the institutional emails of students from the Medical University of Lodz (MS), NMS were invited only through social media. 2.2. Measurement Tools A three-part questionnaire was prepared. The first part concerned general information such as age, gender, income, professional status, the population size of the place of residence and work, previous SARS-CoV-2 infection in participants themselves or their relatives, fear of getting infected, willingness to get vaccinated against SARS-CoV-2, and past medical history of mandatory and recommended vaccinations. The second part focused on their grades in microbiology, clinical immunology, introduction to pediatrics, and infectious diseases courses. The final part included the standardized Depression, Anxiety and Stress Scale-21 Items questionnaire (DASS-21) to measure the intensity of depression, anxiety, and stress. As the DASS-21 scale encompasses the previous week, and the MS were due to receive vaccination from 27 December 2020, the study was performed one week before this date. Each item was rated on a 0–3 scale, so that the total scores ranged from 0 to 63. A higher score suggests more severe depression, anxiety, and/or stress symptoms. The scale is widely used in the Polish population [6]. The internal consistency of the DASS-21, assessed with Cronbach’s α, was sufficient for the study (0.921). 2.3. Data Collection All participants were aware of the study conditions and gave informed consent to participate. Confidentiality and anonymity were maintained and no data that could help identify a responder were collected. The local Bioethics Committee confirmed that, according to Polish law and Good Clinical Practice regulations, the study does not require the approval of a Bioethics Committee (KB nr 542/20) [7]. 2.4. Sample Size Calculation and Statistical Analysis The sample size calculation was performed using a calculator provided by The Uni- versity of British Columbia [8]. The frequency of students who wish to be vaccinated was calculated separately for MS and NMS (94% and 70%, respectively) based on the first fifty questionnaires. To provide a standard α = 0.05 and β = 0.80, the minimum size of each group was 40. The collected data were verified for completeness, quality, and consistency as de- scribed previously [7]. Statistical analysis was performed using STATISTICA 13.1 (TIBCO, Palo Alto, Santa Clara, CA, USA). A level of 5% was used as a significance threshold for all results unless stated otherwise. The distribution of the obtained data was assessed by the Shapiro-Wilk test (p > 0.05 for normal distribution). Data with a normal distri- bution are reported as mean with standard deviation (SD), while non-normal data are presented as median with IQR (1. quartile–3. quartile) [9,10]. The relationship between two independent subgroups was assessed using Student’s t-test for normally distributed Vaccines 2021, 9, 128 3 of 12 data, or the Mann-Whitney U-test for non-normally distributed data. The qualitative data were analyzed using the chi-square test, Yates-corrected chi-square or Fisher’s exact test based on the size of the smallest subgroup (n ≥ 15, 15 > n ≥ 5, 5 > n, respectively) [11]. All qualitative findings are presented as n (%). Finally, binary logistic regression was performed to properly evaluate the eventual facilitators/barriers affecting the willingness to be vaccinated as soon as possible. 3. Results 3.1. Study Group Our study group consisted of 1971 students: 687 (35.23%) MS and 1284 (56.70%) NMS. Their median age was 21 (20–24) and 20 (19–22), respectively. Most of them grew up in the countryside and/or small cities (<50,000 residents) and studied in cities of over 500,000 residents. Details are presented in Table1. Table 1. Study and control group characterization (n = 1971). Medical Students Non-Medical Students Total; n 687 1284 Male; n (%) 242 (35.23%) 728 (56.70%) Median age 21 (20–24) 20 (19–22) Population of the place of employment/study; n (% of complete data): City > 500,000 residents 502 (75.83%) 588 (50.56%) City > 250,000 residents 69 (10.42%) 175 (15.05%) City > 100,000 residents 29 (4.38%) 143 (12.3%) City > 50,000 residents 14 (2.12%) 63 (5.42%) City < 50,000 residents 23 (3.48%) 126 (10.83%) Countryside 25 (3.77%) 68 (5.84%) Place of residence as a child; n (% of complete data) City > 500,000 residents 145 (21.90%) 215 (18.49%) City > 250,000 residents 50 (7.55%) 87 (7.48%) City > 100,000 residents 74 (11.18%) 155 (13.33%) City > 50,000 residents 72 (10.87%) 121 (10.4%) City < 50,000 residents 151 (22.80%) 296 (25.45%) Countryside 170 (25.70%) 289 (24.85%) 3.2.
Load more

Recommended publications
  • Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines
    Review Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines Puna Maya Maharjan 1 and Sunghwa Choe 2,3,* 1 G+FLAS Life Sciences, 123 Uiryodanji-gil, Osong-eup, Heungdeok-gu, Cheongju-si 28161, Korea; punamaya.maharjan@gflas.com 2 G+FLAS Life Sciences, 38 Nakseongdae-ro, Gwanak-gu, Seoul 08790, Korea 3 School of Biological Sciences, College of Natural Sciences, Seoul National University, Gwanak-gu, Seoul 08826, Korea * Correspondence: [email protected] Abstract: The prevalence of the coronavirus disease 2019 (COVID-19) pandemic in its second year has led to massive global human and economic losses. The high transmission rate and the emergence of diverse SARS-CoV-2 variants demand rapid and effective approaches to preventing the spread, diagnosing on time, and treating affected people. Several COVID-19 vaccines are being developed using different production systems, including plants, which promises the production of cheap, safe, stable, and effective vaccines. The potential of a plant-based system for rapid production at a commercial scale and for a quick response to an infectious disease outbreak has been demonstrated by the marketing of carrot-cell-produced taliglucerase alfa (Elelyso) for Gaucher disease and tobacco- produced monoclonal antibodies (ZMapp) for the 2014 Ebola outbreak. Currently, two plant-based COVID-19 vaccine candidates, coronavirus virus-like particle (CoVLP) and Kentucky Bioprocessing (KBP)-201, are in clinical trials, and many more are in the preclinical stage. Interim phase 2 clinical Citation: Maharjan, P.M.; Choe, S. trial results have revealed the high safety and efficacy of the CoVLP vaccine, with 10 times more Plant-Based COVID-19 Vaccines: neutralizing antibody responses compared to those present in a convalescent patient’s plasma.
    [Show full text]
  • BANCOVID, the First D614G Variant Mrna-Based Vaccine Candidate Against SARS
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.29.319061; this version posted September 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. 1 BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS- 2 CoV-2 elicits neutralizing antibody and balanced cellular immune response 3 Juwel Chandra Baray, Md. Maksudur Rahman Khan, Asif Mahmud, Md. Jikrul Islam, Sanat 4 Myti, Md. Rostum Ali, Md. Enamul Haq Sarker, Samir Kumar, Md. Mobarak Hossain 5 Chowdhury, Rony Roy, Faqrul Islam, Uttam Barman, Habiba Khan, Sourav Chakraborty, Md. 6 Manik Hossain, Md. Mashfiqur Rahman Chowdhury, Polash Ghosh, Mohammad Mohiuddin, 7 Naznin Sultana*, Kakon Nag* 8 Globe Biotech Ltd., 3/Ka, Tejgaon I/A, Dhaka – 1208, Bangladesh, 9 *, to whom correspondence should be made. 10 E-mail: [email protected], [email protected] 11 12 13 Key words: COVID, Coronavirus, Lipid nanoparticle, LNP, Vaccination, Immunization, 14 15 16 Abstract 17 Effective vaccine against SARS-CoV-2 is the utmost importance in the current world. More 18 than 1 million deaths are accounted for relevant pandemic disease COVID-19. Recent data 19 showed that D614G genotype of the virus is highly infectious and responsible for almost all 20 infection for 2nd wave. Despite of multiple vaccine development initiatives, there are currently 21 no report that has addressed this critical variant D614G as vaccine candidate. Here we report 22 the development of an mRNA-LNP vaccine considering the D614G variant and 23 characterization of the vaccine in preclinical trial.
    [Show full text]
  • 1. Sars-Cov Nucleocapsid Protein Epitopes and Uses Thereof
    www.engineeringvillage.com Citation results: 500 Downloaded: 4/24/2020 1. SARS-COV NUCLEOCAPSID PROTEIN EPITOPES AND USES THEREOF KELVIN, David; PERSAD, Desmond; CAMERON, Cheryl; BRAY, Kurtis, R.; LOFARO, Lori, R.; JOHNSON, Camille; SEKALY, Rafick-Pierre; YOUNES, Souheil-Antoine; CHONG, Pele Assignee: UNIVERSITY HEALTH NETWORK; BECKMAN COULTER, INC.; UNIVERSITE DE MONTREAL; NATIONAL HEALTH RESEARCH INSTITUTES Publication Number: WO2005103259 Publication date: 11/03/2005 Kind: Patent Application Publication Database: WO Patents Compilation and indexing terms, 2020 LexisNexis Univentio B.V. Data Provider: Engineering Village 2. SARS-CoV-specific B-cell epitope and applications thereof Wu, Han-Chung; Liu, I-Ju; Chiu, Chien-Yu Assignee: National Taiwan University Publication Number: US20060062804 Publication date: 03/23/2006 Kind: Utility Patent Application Database: US Patents Compilation and indexing terms, 2020 LexisNexis Univentio B.V. Data Provider: Engineering Village 3. A RECOMBINANT SARS-COV VACCINE COMPRISING ATTENUATED VACCINIA VIRUS CARRIERS QIN, Chuan; WEI, Qiang; GAO, Hong; TU, Xinming; CHEN, Zhiwei; ZHANG, Linqi; HO, David, D. Assignee: INSTITUTE OF LABORATORY ANIMAL SCIENCE OF CHINESE ACADEMY OF MEDICAL SCIENCES; THE AARON DIAMOND AIDS RESEARCH CENTER; QIN, Chuan; WEI, Qiang; GAO, Hong; TU, Xinming; CHEN, Zhiwei; ZHANG, Linqi; HO, David, D. Publication Number: WO2006079290 Publication date: 08/03/2006 Kind: Patent Application Publication Database: WO Patents Compilation and indexing terms, 2020 LexisNexis Univentio B.V. Data
    [Show full text]
  • Mrna-Based Vaccines to Elicit CD8+ T Cell Immunity
    mRNA-based Vaccines to Elicit CD8+ T Cell Immunity Ans De Beuckelaer Thesis submitted in partial fulfilment of the requirements for the degree of Doctor in Sciences: Biochemistry and Biotechnology 2016 Promoter Prof. Dr. Johan Grooten Co-promoter Dr. Stefaan De Koker Laboratory of Molecular Immunology Department of Biomedical Molecular Biology Faculty of Sciences, Ghent University The research described in this doctoral thesis was performed at the Department of Biomedical Molecular Biology, Faculty of Sciences, Ghent University. Ans De Beuckelaer was supported by a personal fellowship of the IWT (Innovation by Science and Technology). No part of this thesis may be reproduced or published without prior permission of the author. © Ans De Beuckelaer 2016 mRNA- based Vaccines to Elicit CD8+ T cell Immunity Ans De Beuckelaer1 Academic year: 2015- 2016 Promoter: Prof. Dr. Johan Grooten1 Co-Promoter: Dr. Stefaan De Koker2 Examination committee Chair Prof. Dr. Rudi Beyaert1,3 Secretary Prof. Dr. Xavier Saelens1,4 Voting members Prof. Dr. Vanham5,6 Prof. Dr. Karine Breckpot7 Prof. Dr. Katrien Remaut8 1 Department of Biomedical Molecular Research, Ghent University, Ghent, Belgium 2 eTheRNA Immunotherapeutics NV, Niel, Belgium 3 Inflammation Research Center, VIB, UGhent, Ghent, Belgium 4 Medical Biotechnology, VIB, UGhent, Ghent, Belgium 5 Department of Biomedical Sciences, University of Antwerp, Anwterp, Belgium 6 Department of Biomedical Sciendes, Virology Unit, Institute of Tropical Medicine, Antwerp, Belgium 7 Laboratory of Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Univ. Brussel, Brussels, Belgium 8 Laboratory for General Biochemistry and Physical Pharmacy, Faculty of Pharaceutical Sciences, UGhent, Ghent, Belgium TABLE OF CONTENT List of Abbreviations 8 Summary 13 Samenvatting 17 Introduction 21 CHAPTER 1.
    [Show full text]
  • Mcmx: a Proposal for a Federal Authority to Enhance Speed, Scale and Access to Medical Countermeasures
    MCMx: A Proposal for a Federal Authority to Enhance Speed, Scale and Access to Medical Countermeasures Findings from the Program in Global Public Policy and Social Change Medical Countermeasures Taskforce: Partnering for Public Good Authors Kendall Hoyt, Geisel School of Medicine, Dartmouth College Margaret Bourdeaux, Harvard Medical School Annmarie Sasdi, Harvard Medical School May 28, 2021 PROGRAM IN GLOBAL PUBLIC POLICY AND SOCIAL CHANGE TASK FORCE MEMBERS Katrine Thor Andersen Deputy Director, Global Health, William and Melinda Gates Foundation Thomas J. Bollyky Director, Global Health Program, Council on Foreign Relations Rick Bright, PhD Senior Vice President, Pandemic Prevention & Response, Health Initiative, The Rockefeller Foundation Philip Dormitzer, MD, PhD Vice President and Chief Scientific Officer Viral Vaccines, Pfizer Rebecca Fish President, Hart Ledge Consulting Bruce Gellin, MD, MPH President, Global Immunization, Sabin Vaccine Institute Arpa (Shah) Garay President, Global Pharmaceuticals, Commercial Analytics, Digital Marketing, Merck & Co. Jonathan P. Gertler, MD Managing Partner and CEO Of Back Bay Life Science Advisors and Managing Director, Bioventures Investors Medtech Funds Robert V. House, PhD, FATS Senior Vice President, Government Contracts, Ology Bioservices Kendall Hoyt, PhD Assistant Professor, Geisel School of Medicine, Dartmouth College Heather Ignatius Director, U.S. and Global Policy and Advocacy, PATH Ryan Morhard Ginkgo Bioworks Jake Reder, PhD CEO, Celdara Medical James Robinson Vice Chair, The Coalition for Epidemic Preparedness Innovations Julia Barnes-Weise, J.D., CFP Executive Director, The Global Healthcare Innovation Alliance Accelerator (GHIAA) Charlie Weller Head of Vaccines, Wellcome Trust 2 PROGRAM IN GLOBAL PUBLIC POLICY AND SOCIAL CHANGE CONTENTS I. Introduction II. MCMx Mission III. MCMx Strategic Plan: Creating a Research and Development Blueprint for MCMs in Future Outbreaks A.
    [Show full text]
  • Download Preprint
    1 Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 2 SARS-CoV-2 and variants of concern 3 4 Authors: Thibault Fiolet1*, Yousra Kherabi2,3, Conor-James MacDonald1, Jade Ghosn2,3, Nathan 5 Peiffer-Smadja2,3,4 6 7 1Paris-Saclay University, UVSQ, INSERM, Gustave Roussy, "Exposome and Heredity" team, CESP 8 UMR1018, Villejuif, France 9 2Université de Paris, IAME, INSERM, Paris, France 10 11 3Infectious and Tropical Diseases Department, Bichat-Claude Bernard Hospital, AP-HP, Paris, France 12 13 4National Institute for Health Research Health Protection Research Unit in Healthcare Associated 14 Infections and Antimicrobial Resistance, Imperial College, London, UK 15 16 *Corresponding author: 17 Email: [email protected] 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 1 48 Abstract 49 Vaccines are critical cost-effective tools to control the COVID-19 pandemic. However, the emergence 50 of more transmissible SARS-CoV-2 variants may threaten the potential herd immunity sought from 51 mass vaccination campaigns. 52 The objective of this study was to provide an up-to-date comparative analysis of the characteristics, 53 adverse events, efficacy, effectiveness and impact of the variants of concern (Alpha, Beta, Gamma and 54 Delta) for fourteen currently authorized COVID-19 vaccines (BNT16b2, mRNA-1273, AZD1222, 55 Ad26.COV2.S, Sputnik V, NVX-CoV2373, Ad5-nCoV, CoronaVac, BBIBP-CorV, COVAXIN, 56 Wuhan Sinopharm vaccine, QazCovid-In, Abdala and ZF200) and two vaccines (CVnCoV and NVX- 57 CoV2373) currently in rolling review in several national drug agencies.
    [Show full text]
  • Dendritic Cell Targets for Self-Replicating RNA Vaccines Kenneth C
    Blood of & al L n y r m u p o h J Journal of Blood & Lymph McCullough, et al., J Blood Lymph 2015, 5:1 ISSN: 2165-7831 DOI: 10.4172/2165-7831.1000132 Mini Review Open access Dendritic Cell Targets for Self-Replicating RNA Vaccines Kenneth C. McCullough*, Panagiota Milona, Thomas Démoulins, Pavlos Englezou and Nicolas Ruggli Institute of Virology and Immunology, 3147 Mittelhaeusern, Switzerland *Corresponding author: Kenneth McCullough, Institute of Virology and Immunology, Sensemattstrasse 293, CH-3147 Mittelhäusern, Switzerland, Tel: +41-31-848-9262; E-mail: [email protected] Rec date: November 25, 2014, Acc date: January 20, 2015, Pub date: January 30, 2015 Copyright: © 2015 McCullough KC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Mini Review protect the RNA as well as enhancing its delivery to cells, for which interaction with DCs would prove a major contribution to Keywords: Dendritic cells; Replicon RNA; Self-replicating vaccines; development of immune defences. Figure 1 summarises main elements Nano particulate delivery contained in the present review below, including the advantages offered when applying biodegradable, nanoparticulate vehicles for Advances in Vaccine Development delivery of self-amplifying replicon RNA to DCs. Vaccination is the cornerstone for controlling many pathogen infections [1-8], and is also under scrutiny for cancer Delivery to Dendritic Cells Immunoprophylaxis/immunotherapy [9,10]. Induction of both Vaccine delivery to DCs is an important consideration due to their antibody and cell-mediated immune (CMI) defences is preferable for essential roles in immune defence development [8,17,19,21-24] – DCs ensuring robust immune defence against most pathogen infections, are referred to as the “professional antigen-presenting cells”.
    [Show full text]
  • Confronting the Threat of SARS‑Cov‑2: Realities, Challenges and Therapeutic Strategies (Review)
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 21: 155, 2021 Confronting the threat of SARS‑CoV‑2: Realities, challenges and therapeutic strategies (Review) RUIXUE WANG1, XIAOSHAN LUO2, FANG LIU1 and SHUHONG LUO2 Departments of 1Basic Medicine and Biomedical Engineering and 2Laboratory Medicine, School of Stomatology and Medicine, Foshan University, Foshan, Guangdong 528000, P.R. China Received August 1, 2020; Accepted November 2, 2020 DOI: 10.3892/etm.2020.9587 Abstract. The novel coronavirus (SARS‑CoV‑2) appeared Contents in2019 in Wuhan, China, and rapidly developed into a global pandemic. The disease has affected not only health care 1. Introduction systems and economies worldwide but has also changed the 2. Virology lifestyles and habits of the majority of the world's popula‑ 3. Epidemiology tion. Among the potential targets for SARS‑CoV‑2 therapy, 4. Mechanism of SARS‑CoV‑2 infection the viral spike glycoprotein has been studied most intensely, 5. Clinical manifestations and diagnosis due to its key role in mediating viral entry into target cells 6. Treatments and inducing a protective antibody response in infected indi‑ 7. Vaccines viduals. In the present manuscript the molecular mechanisms 8. Conclusions and outlook that are responsible for SARS‑CoV‑2 infection are described and a progress report on the status of SARS‑CoV‑2 research is provided. A brief review of the clinical symptoms of the 1. Introduction condition and current diagnostic methods and treatment plans for SARS‑CoV‑2 are also presented and the progress Following the emergence of severe acute respiratory syndrome of preclinical research into medical intervention against (SARS) coronavirus (SARS‑CoV) in 2003 and Middle East SARS‑CoV‑2 infection are discussed.
    [Show full text]
  • Impfstoffkandidaten Gegen SARS-Cov-2, Die Sich Aktuell In
    Impfstoffkandidaten gegen SARS-CoV-2, die sich aktuell in klinischer Prüfung befinden (Vereinfachte Übersicht, kein Anspruch auf Vollständigkeit, alle Angaben ohne Gewähr; Stand: 12.03.2021; die Reihenfolge der Darstellung wurde der Abbildung Strategien der SARS-CoV-2- Impfstoffentwicklung angeglichen sowie eine weitere Kategorie hinzugefügt; inhaltliche Änderungen im Vergleich zur Vorversion sind farblich gekennzeichnet) IMPFSTOFF-PLATTFORM/- ENTWICKLER KLINISCHE STUDIEN ART (HAUPTSITZ) (STUDIENORT)* VIRUSBASIERTE IMPFSTOFFE Inaktivierter Virusimpfstoff Wuhan Institute of Biological Phase 1/2 (China) (SARS-CoV-2) Products/Sinopharm (China) Phase 3 (UAE) Phase 3 (Marokko) Phase 3 (Peru) Phase 3 (Bahrain, Ägypten, Jordanien, UAE) Inaktivierter Virusimpfstoff Beijing Institute of Biological Phase 1/2 (China) BBIBP-CorV (SARS-CoV-2) Products/Sinopharm (China) Phase 3 (UAE) Phase 3 (Argentinien) Phase 3 (Bahrain, Ägypten, Jordanien, UAE) Inaktivierter Virusimpfstoff Sinovac Phase 1/2 (China) CoronaVac (China) Phase 1/2 (China) (SARS-CoV-2) Phase 1/2 (China) Phase 2 (Brasilien, immunsupprimierte Patienten) Phase 3 (Brasilien) Phase 3 (Indonesien) Phase 3 (Türkei) Phase 3 (China) Phase 3 (Chile) Phase 4 (Brasilien; Rekru- tierung noch nicht begonnen) Phase 4 (Brasilien) Phase 4 (Hong Kong, Patienten mit chron. Lebererkrankungen; Rekrutierung noch nicht begonnen) Inaktivierter Virusimpfstoff Institute of Medical Biology, Phase 1 (China) (SARS-CoV-2) Chinese Academy of Medical Phase 1/2 (China) Sciences (China) Nationale Lenkungsgruppe Impfen,
    [Show full text]
  • Ethical Guidelines for Conducting Research Studies Involving Human Subjects
    Bangladesh Medical Research Council Ethical Guidelines for Conducting Research Studies Involving Human Subjects CONTENTS SECTION – A 01. Ethical perspective of BMRC 1 1.1 Role of BMRC 1 1.2 Objectives of the ethical approval 3 1.3 Research requires ethical approval 3 1.4 Background 3 1.5 Definition of Ethics 4 1.6 General Ethical Principles 5 1.7 Important Issues in Ethical Consideration 5 1.8 Vulnerable population 02. International Guidelines on Ethics in Health Research 6 03. Issues in Ethical Clearance 7 3.1 Informed Consent 7 3.2. Confidentiality 10 3.3 Inducement 11 3.4 Compensation 04. Scientific Misconduct 12 05. Participants like Pregnant / Nursing women and Children 14 06. Post Trial Access 16 07. International collaboration / assistance in Biomedical / Health Research 16 08. Researcher’s relation with media and publication 18 09. Guideline on Research Ethics as per national health research strategies 19 SECTION – B 10. Interventional Studies 21 10.1. Drug Trial 22 10.1.1 Special Considerations 22 10.1.2. Phases of Clinical Trials 24 10.1.3. Special studies 26 10.1.4. Dissolution Studies 26 10.1.5. Special Concerns 27 10.1.5.1. Multicenter Trials 27 10.1.5.2. Contraceptives 28 10.1.5.3. Randomized Controlled Trial (RCT) 28 10.2. Vaccine Trials 30 10.2.1. Combination Vaccines 31 10.2.2. Special Concerns 32 10.3. Trials with Surgical Procedures/Medical Devices 33 10.3.1. Definition of Device 34 10.4. Diagnostic Agents- Use of Radio-Active Materials and X-Ray 35 10.5.
    [Show full text]
  • Ten Technologies to Fight Coronavirus
    Ten technologies to fight coronavirus IN-DEPTH ANALYSIS EPRS | European Parliamentary Research Service Author: Mihalis Kritikos Scientific Foresight Unit (STOA) EN PE 641.543 – April 2020 Ten technologies to fight coronavirus As the coronavirus (Covid-19) pandemic spreads, technological applications and initiatives are multiplying in an attempt to control the situation, treat patients in an effective way and facilitate the efforts of overworked healthcare workers, while developing new, effective vaccines. This analysis examines in detail how ten different technological domains are helping the fight against this pandemic disease by means of innovative applications. It also sheds light on the main legal and regulatory challenges, but also on the key socio-ethical dilemmas that the various uses of these technologies pose when applied in a public-health emergency context such as the current one. A scan of the technological horizon in the context of Covid-19 indicates that technology in itself cannot replace or make up for other public policy measures but that it does have an increasingly critical role to play in emergency responses. Covid-19, as the first major epidemic of our century, represents an excellent opportunity for policy-makers and regulators to reflect on the legal plausibility, ethical soundness and effectiveness of the deployment of emerging technologies under time pressure. Striking the right balance will be crucial for maintaining the public's trust in evidence-based public health interventions. I EPRS | European Parliamentary Research Se vice AUTHOR This in-depth analysis has been written by Mihalis Kritikos of the Scientific Foresight Unit (STOA) within the Directorate-General for Parliamentary Research Services (EPRS) of the Secretariat of the European Parliament.
    [Show full text]
  • The Current Status of Malaria Vaccines
    BioDrugs 1998 Aug; 10 (2): 123-136 IMMUNOLOGY-BASED AGENTS 1173-8804/98/0008-0123/$07.00/0 © Adis International Limited. All rights reserved. The Current Status of Malaria Vaccines José A. Stoute and W. Ripley Ballou Department of Immunology, Division of Communicable Diseases and Immunology, Walter Reed Army Institute of Research, Washington DC, USA Contents Abstract . 123 1. Vaccines Targeting the Pre-Erythrocytic Stage . 124 1.1 Vaccines That Target the Sporozoite . 124 1.2 Other Pre-Erythrocytic Stage Vaccines . 127 2. Vaccines Targeting the Asexual Erythrocytic Stage . 127 3. Transmission-Blocking Vaccines . 129 4. Major Roadblocks to a Successful Malaria Vaccine . 130 5. New Approaches to Malaria Vaccine Development . 131 5.1 Multistage, Multicomponent Vaccines . 131 5.2 DNA Vaccines . 132 Abstract A vaccine against Plasmodium falciparum malaria is needed now more than ever due the resurgence of the parasite and the increase in drug resistance. How- ever, success in developing an effective malaria vaccine has been elusive. Among pre-erythrocytic antigens, the major antigen coating the surface of the sporozoite, the circumsporozoite protein (CS), has been, and continues to be, the major target for vaccine development. Despite initial limited success with CS- based vaccines, the use of new adjuvant formulations has led to the development of a promising candidate (the RTS,S vaccine) which has shown significant effi- cacy in a preliminary trial. In addition to CS, many other malaria antigens have been identified that play an important role in the parasite life cycle which are being considered for, or are currently undergoing, clinical trials. Among the blood stage antigens, the mero- zoite surface protein 1 (MSP-1) is the most promising vaccine candidate.
    [Show full text]